IRIS
BUTI, Sebastiano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.970
EU - Europa 4.530
AS - Asia 2.256
AF - Africa 53
SA - Sud America 30
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.849
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.924
IE - Irlanda 1.560
SG - Singapore 1.447
SE - Svezia 1.218
IT - Italia 1.000
CN - Cina 621
DE - Germania 153
FI - Finlandia 132
AT - Austria 126
FR - Francia 85
IN - India 77
BE - Belgio 53
GB - Regno Unito 45
CI - Costa d'Avorio 44
CA - Canada 41
NL - Olanda 28
CZ - Repubblica Ceca 26
TR - Turchia 26
UA - Ucraina 25
BR - Brasile 23
IR - Iran 21
JP - Giappone 18
RU - Federazione Russa 16
HK - Hong Kong 12
LT - Lituania 10
ES - Italia 9
CH - Svizzera 8
AU - Australia 6
LU - Lussemburgo 6
MA - Marocco 6
KR - Corea 5
PH - Filippine 5
PL - Polonia 5
BG - Bulgaria 4
MX - Messico 4
VN - Vietnam 4
CO - Colombia 3
GR - Grecia 3
HR - Croazia 3
ID - Indonesia 3
IL - Israele 3
MD - Moldavia 3
TW - Taiwan 3
A1 - Anonimo 2
AR - Argentina 2
DK - Danimarca 2
EG - Egitto 2
KZ - Kazakistan 2
OM - Oman 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BS - Bahamas 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
HU - Ungheria 1
IQ - Iraq 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 12.849
Salva come PNG Salva come JPEG
Città #
Chandler 1.909
Dublin 1.547
Singapore 1.107
Boardman 551
Ashburn 550
Princeton 298
Beijing 197
Shanghai 195
Vienna 126
Ann Arbor 122
Helsinki 113
Milan 107
Parma 106
New York 105
Des Moines 88
Santa Clara 82
Rome 74
Wilmington 69
Bologna 64
Marseille 51
Bremen 50
Abidjan 44
Brussels 43
Los Angeles 36
Verona 34
Munich 31
Dearborn 29
Pune 29
Chicago 27
Seattle 26
Jacksonville 25
Genoa 22
London 22
Modena 20
Nanjing 20
Toronto 20
Florence 17
Reggio Emilia 17
San Mateo 15
Torrile 14
Dallas 13
Frankfurt am Main 13
Izmir 13
Arezzo 12
Brno 12
Olomouc 12
Washington 12
Atlanta 11
Jinan 11
Tokyo 11
Borås 10
Naples 10
Turin 10
Fairfield 9
Fremont 9
Guangzhou 9
Hangzhou 9
New Delhi 9
Rockville 9
Scandiano 9
Sorbolo 9
Trento 9
Woodbridge 9
Falls Church 8
Fort Worth 8
Nanchang 8
Norwalk 8
Paris 8
Wuhan 8
Amsterdam 7
Forest City 7
Hong Kong 7
Houston 7
Istanbul 7
Kunming 7
Rio Saliceto 7
Sassuolo 7
Shenyang 7
São Paulo 7
Assago 6
Boston 6
Brescia 6
Catania 6
Hebei 6
Louvain-la-Neuve 6
Meknes 6
Ottawa 6
Padova 6
Prineville 6
Sacramento 6
Tianjin 6
West Jordan 6
Cavriago 5
Chennai 5
Deiva Marina 5
Delhi 5
Gela 5
Hefei 5
Kish 5
Menlo Park 5
Totale 8.478
Salva come PNG Salva come JPEG
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 117
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 104
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 97
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 88
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 87
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 87
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations 86
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 77
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 76
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 76
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 76
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 73
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 73
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 70
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 70
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 69
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 69
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 67
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 66
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 66
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 66
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 64
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 64
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 64
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 63
LA PRATICA CLINICA - Everolimus nel carcinoma renale papillare 62
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 60
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 60
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma. 58
Interleuchina-2 (IL-2) più Interferone-α (IFN-α) a basse dosi come terapia adiuvante nel carcinoma a cellule renali (RCC) operabile. Uno studio indipendente di fase III, randomizzato, multicentrico, del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 58
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 57
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 57
A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study 57
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial 57
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 56
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 56
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 55
Primo caso di carcinoma vescicale sarcomatoide associato a BKV in paziente trapiantato di rene: possibile ruolo dell’immunoistochimica per BKV-TAg e p16 su citologia urinaria nella diagnosi precoce di neoplasia 55
Natural history of renal metastases to the pancreas: do not operate all and always? 55
Review on radiological evolution of COVID-19 pneumonia using computed tomography 55
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 55
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors 54
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial) 54
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer 53
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 53
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 52
Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta–lesion attenuation difference (ALAD) on contrast-enhanced CT 52
A wide skull osteolytic metastasis in advanced breast cancer 51
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 50
Long-term clinical results with low-dose interleukin-2 and interferon-alpha in 145 patients with metastatic renal cell carcinoma” (Poster) 50
Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab 50
Long-term clinical results with low-dose Interleukin-2 and Interferon-α in 145 patients with metastatic renal cell carcinoma 50
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going 50
TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)-Liquid biopsy for biomarkers discovery 49
Diabete e neoplasie in una coorte di soggetti diabetici ospedalizzati 49
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 49
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 48
Sopravvivenza e risposta alla terapia in 139 pazienti affetti da Carcinoma Renale Metastatico (CRm) trattati con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) a basse dosi. Influenza del rischio prognostico rilevato alla diagnosi 48
Retrospective analysis of patients undergoing stereotactic body radiotherapy (SBRT) in secondary non-bone lesions of metastatic renal cell carcinoma (mRCC) in treatment with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors 48
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 47
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 47
Very late recurrence of an apparently benign pheochromocytoma 47
Dose-dense chemotherapy with Docetaxel, Cisplatin, folinic acid and 5-fluorouracil (TCAF DD) in metastatic gastric cancer (MGC): A feasibility study 47
Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers 47
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 46
Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP) 46
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study 46
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC) 46
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 46
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 45
Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial) 45
Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC) 45
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 45
Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC) 45
Renal metastases to pancreas: do not operate all and always? 45
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report 45
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials 45
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 45
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 45
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer 45
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis 44
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 44
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 44
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study 44
Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC) 44
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) 44
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWN): A preliminary report 44
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer 44
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients? 44
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study 43
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 43
Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets 43
Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC) 43
Phase III, randomized, multicentre trial of maintenance of biotherapy with Interleukin-2 (IL-2) and Interferon-alpha (IFN) for metastatic renal cell cancer (RCC) 43
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 43
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 43
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 43
Safety of targeted therapies (TTs) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD) 42
Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial 42
Cabozantinib in RCC: only a METEOR or a rising star? 42
Totale 5.564
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.761
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020188 0 0 0 0 16 40 22 21 19 43 19 8
2020/2021205 3 6 10 23 13 34 13 19 37 19 16 12
2021/20221.466 9 10 13 30 5 117 319 100 61 25 100 677
2022/20236.059 710 740 558 380 457 586 80 316 1.925 27 203 77
2023/20242.659 135 225 103 109 290 542 204 125 178 154 189 405
2024/20252.659 157 697 754 408 643 0 0 0 0 0 0 0
Totale 13.428